Puma commences Phase II trial of alisertib for breast cancer treatment
Puma Biotechnology has commenced the Phase II trial, ALISCA-Breast1, to evaluate oral alisertib, a selective inhibitor of aurora kinase A,…
Oncology
-
-
MSD reports topline outcomes from Phase III NSCLC trial of pembrolizumab
MSD has reported positive topline outcomes from the Phase III MK-3475A-D77 study assessing the noninferiority of subcutaneous Keytruda (pembrolizumab) administration,…
-
Toragen reports positive results from trial of TGN-S11 for HPV-related cancer
US-based biotechnology company Toragen has reported positive safety outcomes from a Phase I trial of TGN-S11, its small molecule drug…
-
Prostate cancer: Three drug trials to watch
Today (19 November) marks International Men’s Day with the theme for 2024 being Men's Health Champions, shining a light on…
-
BioNTech signs agreement to acquire Biotheus
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a programmed death-ligand 1…
-
Syros stock craters after lead cancer therapy flops in Phase III trial
Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial…
-
OncoResponse reports data from Phase I solid tumour treatment trial
OncoResponse has unveiled the outcomes from the Phase I trial of OR502, a humanised anti-leukocyte immunoglobulin like receptor B2 (LILRB2)…
-
Castle boasts melanoma test’s capacity to reduce unnecessary testing
Castle Biosciences has released data from a multi-centre DECIDE study showing the impact of integrating its DecisionDx-Melanoma test results into…
-
Tizona’s TTX-080 colorectal cancer trial expands with new arms
Tizona Therapeutics has expanded its ongoing Phase Ib clinical trial of TTX-080, a novel antibody targeting human leukocyte antigen-G (HLA-G),…
-
Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial
US-based company Biofrontera has announced topline results from a Phase III trial evaluating its drug-device therapy, Ameluz gel and photodynamic…
